高危急性髓系白血病诊疗进展：第55届美国血液学会年会报道

Diagnostic and therapeutic advances of high risk acute myeloid leukemia： reports from the 55th ASH annual meeting

近年来,在急性髓系白血病（AML）中发现了多种染色体异常和基因突变并确定了其预后价值.提高对白血病生物学特点的认识有助于对其进行准确的诊断、预后分层以及监测微小残留病变,有利于开发靶向治疗药物和提高预后.文章就2013年美国血液学会年会上关于高危AML的染色体和基因突变特点以及临床试验中的新药研究现状进行综述.

Acute myeloid leukemia （AML） is a group of heterogeneous diseases with diverse genetic abnormalities,variable responsiveness to therapy and prognosis.In recent years,a lot of information has become available regarding chromosome and gene mutations that occur in AML and their influence on prognosis.Improvements in the understanding of molecular biology of AML are critical for accurate diagnosis.risk stratification,monitoring of minimal residual disease and provides opportunities to develop targeted therapies and improve the clinical outcome.This article reviewed chromosome abnormalities and characteristic gene mutations,and discussed their clinical signiflcances and presented new drugs in clinical trials presented in the 55th ASH annual meeting.